(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Dana Rathkopf discussing the clinical activity of BMS-986365 (CC-94676) in heavily ...

Abstract: This paper presents a techno-economic analysis and comparison of two battery management system (BMS) topologies namely centralized BMS (CBMS) and distributed BMS (DBMS). Testing, ...

BMS achieved non-GAAP EPS of $6.15 for the full year, a substantial improvement from $1.15 in 2024. Credit: Piotr Swat / Shutterstock.com. Bristol Myers Squibb (BMS) has reported full-year 2025 ...

CEO Christopher Boerner opened by highlighting, “2025 was a year of focused execution across the business. We believe our results further demonstrate the ongoing strength in our growth portfolio as we ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor ...

Bristol-Myers Squibb (BMS) reported stronger-than-expected earnings for the fourth quarter of 2025, with earnings per share (EPS) reaching $1.26, surpassing the anticipated $1.12. Revenue also ...

Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor Relations website at http ...

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake. Bristol Myers Squibb sales hit $12.5 ...

OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...

Abstract: Electric vehicles (EVs) hold great potential as a sustainable mode of transportation. Nevertheless, issues with their effectiveness and safety still exist, particularly with relation to ...

Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.